Cargando…
Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention
Coronavirus disease 2019 (COVID-19) has become a major health burden worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute phase of COVID-19 management has been established, there is still a long way to go to evaluate the long-term clinical course or manage compli...
Autores principales: | Yoon, Hee-Young, Uh, Soo-Taek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537661/ https://www.ncbi.nlm.nih.gov/pubmed/35722706 http://dx.doi.org/10.4046/trd.2022.0053 |
Ejemplares similares
-
Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
por: Ogata, Hiroaki, et al.
Publicado: (2021) -
Pulmonary Rehabilitation in Coronavirus Disease 2019 Patients
por: Menekşeoğlu, Ahmet Kıvanç, et al.
Publicado: (2022) -
Impact of Government Intervention in Response to Coronavirus Disease 2019
por: Won, Jin-Young, et al.
Publicado: (2022) -
Coronavirus disease 2019 vaccination‐induced acute exacerbation in idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2022) -
Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report
por: Kudo, Risa, et al.
Publicado: (2023)